Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ci-218872 SCHEMBL1320758 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL15024914 | 0.91 | KDM4E (0.83) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11383868 | 0.85 | CYP1A2 (0.74) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11626491 | 0.83 | CYP1A2 (0.71) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11624780 | 0.83 | KDM4E (0.71) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11628686 | 0.82 | KDM4E (0.69) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11626977 | 0.82 | KDM4E (0.69) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11623975 | 0.81 | KDM4E (0.68) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11625699 | 0.81 | CYP1A2 (0.68) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 | |
| SCHEMBL11388563 | 0.81 | CYP1A2 (0.68) | KDM4EHSD17B10CYP1A2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | claimed |
| CN-118787751-A | Use of LSD1 inhibitors in combination with drugs for the treatment of cancer | 中国科学院上海药物研究所 | 2024-10-18 | — | — | CN | claimed |
| WO-2024213057-A1 | USE OF COMBINATION OF LSD1 INHIBITOR AND DRUG TO TREAT CANCER | 中国科学院上海药物研究所 | 2024-10-17 | — | — | WO | claimed |
| EP-4405049-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | The Regents of the University of California (US) | 2024-07-31 | — | — | EP | claimed |
| US-20230381125-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-30 | — | — | US | claimed |
| EP-4217002-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | The Regents of the University of California (US) | 2023-08-02 | — | — | EP | claimed |
| WO-2023101899-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING SJOGREN'S SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023048781-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-30 | — | — | WO | claimed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| WO-2022067044-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | claimed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240390311-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-28 | — | — | US | disclosed |
| CN-118787751-A | Use of LSD1 inhibitors in combination with drugs for the treatment of cancer | 中国科学院上海药物研究所 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024213057-A1 | USE OF COMBINATION OF LSD1 INHIBITOR AND DRUG TO TREAT CANCER | 中国科学院上海药物研究所 | 2024-10-17 | — | — | WO | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3698832-B1 | METHODS AND DEVICES FOR SMOKING URGE RELIEF | FONTEM HOLDINGS 1 BV (NL) | 2022-07-13 | — | — | EP | disclosed |
| EP-4017874-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | Coda Biotherapeutics, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | disclosed |
| WO-2022067044-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | KDM4E 4711/4885HSD17B10 4285/4885CYP1A2 4875/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | KDM4E 4673/4885HSD17B10 4107/4885CYP1A2 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.